BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 32130814)

  • 1. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.
    Ahdoot M; Wilbur AR; Reese SE; Lebastchi AH; Mehralivand S; Gomella PT; Bloom J; Gurram S; Siddiqui M; Pinsky P; Parnes H; Linehan WM; Merino M; Choyke PL; Shih JH; Turkbey B; Wood BJ; Pinto PA
    N Engl J Med; 2020 Mar; 382(10):917-928. PubMed ID: 32130814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-biopsy 3-Tesla MRI and targeted biopsy of the index prostate cancer: correlation with robot-assisted radical prostatectomy.
    Patel U; Dasgupta P; Challacombe B; Cahill D; Brown C; Patel R; Kirby R
    BJU Int; 2017 Jan; 119(1):82-90. PubMed ID: 27153933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Magnetic Resonance Imaging Targeting on Pathologic Upgrading and Downgrading at Prostatectomy: A Systematic Review and Meta-analysis.
    Weinstein IC; Wu X; Hill A; Brennan D; Omil-Lima D; Basourakos S; Brant A; Lewicki P; Al Hussein Al Awamlh B; Spratt D; Bittencourt LK; Scherr D; Zaorsky NG; Nagar H; Hu J; Barbieri C; Ponsky L; Vickers AJ; Shoag JE
    Eur Urol Oncol; 2023 Aug; 6(4):355-365. PubMed ID: 37236832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy.
    Gandaglia G; Ploussard G; Valerio M; Mattei A; Fiori C; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Moschini M; Zamboni S; Rakauskas A; Tian Z; Karakiewicz PI; De Cobelli F; Porpiglia F; Montorsi F; Briganti A
    Eur Urol; 2020 Jun; 77(6):733-741. PubMed ID: 31547938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of prebiopsy magnetic resonance imaging on biopsy and radical prostatectomy grade concordance.
    Shoag JE; Cai PY; Gross MD; Gaffney C; Li D; Mao J; Nowels M; Scherr DS; Sedrakyan A; Hu JC
    Cancer; 2020 Jul; 126(13):2986-2990. PubMed ID: 32320063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.
    Han JS; Toll AD; Amin A; Carter HB; Landis P; Lee S; Epstein JI
    Urology; 2012 Oct; 80(4):883-8. PubMed ID: 22921697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Added Value of Concomitant Systematic and Fusion Targeted Biopsies for Grade Group Prediction Based on Radical Prostatectomy Final Pathology on Positive Magnetic Resonance Imaging.
    Ploussard G; Beauval JB; Lesourd M; Almeras C; Assoun J; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
    J Urol; 2019 Dec; 202(6):1182-1187. PubMed ID: 31246548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biopsy-Integrated 3D Magnetic Resonance Imaging Modeling of Prostate Cancer and Its Application for Gleason Grade and Tumor Laterality Assessment.
    Kim J; Lim B; Jeong IG; Ro JY; Go H; Cho YM; Park KJ
    Arch Pathol Lab Med; 2023 Feb; 147(2):159-166. PubMed ID: 35512234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate magnetic resonance imaging-targeted biopsy global grade correlates better than highest grade with prostatectomy grade.
    Ren J; Melamed J; Taneja SS; Wysock JS; Huang WC; Lepor H; Deng FM
    Prostate; 2023 Mar; 83(4):323-330. PubMed ID: 36461793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The oncologic risk of magnetic resonance imaging-targeted and systematic cores in patients treated with radical prostatectomy.
    Gaffney CD; Tin AL; Fainberg J; Fine S; Jibara G; Touijer K; Eastham J; Scardino P; Laudone V; Vickers AJ; Ehdaie B
    Cancer; 2023 Dec; 129(23):3790-3796. PubMed ID: 37584213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy.
    Siddiqui MM; Rais-Bahrami S; Truong H; Stamatakis L; Vourganti S; Nix J; Hoang AN; Walton-Diaz A; Shuch B; Weintraub M; Kruecker J; Amalou H; Turkbey B; Merino MJ; Choyke PL; Wood BJ; Pinto PA
    Eur Urol; 2013 Nov; 64(5):713-719. PubMed ID: 23787357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.
    Druskin SC; Mamawala M; Tosoian JJ; Epstein JI; Pavlovich CP; Carter HB; Trock BJ
    J Urol; 2019 Jan; 201(1):98-104. PubMed ID: 30114397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
    King CR; McNeal JE; Gill H; Presti JC
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy.
    Arsov C; Becker N; Rabenalt R; Hiester A; Quentin M; Dietzel F; Antoch G; Gabbert HE; Albers P; Schimmöller L
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2061-8. PubMed ID: 26013424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
    Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
    JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study.
    Elkhoury FF; Felker ER; Kwan L; Sisk AE; Delfin M; Natarajan S; Marks LS
    JAMA Surg; 2019 Sep; 154(9):811-818. PubMed ID: 31188412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent Discordance in Grade, Stage, and NCCN Risk Stratification in Men Undergoing Targeted Biopsy and Radical Prostatectomy.
    Alshak MN; Patel N; Gross MD; Margolis D; Hu JC
    Urology; 2020 Jan; 135():117-123. PubMed ID: 31568795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of MRI-Targeted in-Bore Prostate Biopsy According to the Gleason Score with Postprostatectomy Histopathologic Control--a Targeted Biopsy-Only Strategy with Limited Number of Cores.
    Garmer M; Busch M; Mateiescu S; Fahlbusch DE; Wagener B; Grönemeyer DH
    Acad Radiol; 2015 Nov; 22(11):1409-18. PubMed ID: 26343218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.